GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-23. Numbers and descriptions here follow the published literature rather than marketing material.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
==== United States ==== Baptist, Edward (2016). The Half Has Never Been Told: Slavery and the Making of American Capitalism. Basic Books. ISBN 978-0-465-09768-5. Beckert, Sven; Rockman, Seth, eds. (2016). Slavery's Capitalism: A New History of American Economic Development. University of Pennsylvania Press. ISBN 978-0-8122-2417-7. Berlin, Ira (2009). Many Thousands Gone: The First Two Centuries of Slavery in North America. Harvard University Press. ISBN 978-0-674-02082-5. Berlin, Ira; Favreau, Marc; Miller, Steven (2011). Remembering Slavery: African Americans Talk About Their Personal Experiences of Slavery and Freedom. New Press. ISBN 978-1-59558-763-3. Blackmon, Douglas A. (2012). Slavery by Another Name: The re-enslavement of black americans from the civil war to World War Two. Icon Books Limited. ISBN 978-1-84831-413-9. Boles, John B. (2015). Black Southerners, 1619–1869. University Press of Kentucky. p. 3. ISBN 978-0-8131-5786-3. Engerman, Stanley Lewis (1999). Terms of Labor: Slavery, Serfdom, and Free Labor. Stanford, CA: Stanford University Press. ISBN 978-0-8047-3521-6. Genovese, Eugene D. (2011). Roll, Jordan, Roll: The World the Slaves Made. Knopf Doubleday Publishing Group. ISBN 978-0-307-77272-5. King, Richard H.; Genovese, Eugene (1977). "Marxism and the Slave South". American Quarterly. 29 (1): 117. doi:10.2307/2712264. ISSN 0003-0678. JSTOR 2712264. Mintz, S. "Slavery Facts & Myths". Digital History. Archived from the original on November 6, 2006. Morgan, Edmund Sears (1975). American Slavery, American Freedom: The Ordeal of Colonial Virginia.
== Recorded human poisonings == Though fatalities from solanine poisoning are rare, there have been several notable cases of human solanine poisonings. Between 1865 and 1983, there were around 2000 documented human cases of solanine poisoning, with most recovering fully and 30 deaths. Because the symptoms are similar to those of food poisoning, it is possible that there are many undiagnosed cases of solanine toxicity. In 1899, 56 German soldiers fell ill due to solanine poisoning after consuming cooked potatoes containing 0.24 mg of solanine per gram of potato. There were no fatalities, but a few soldiers were left partially paralyzed and jaundiced. In 1918, there were 41 cases of solanine poisoning in people who had eaten a bad crop of potatoes with 0.43 mg solanine/g potato with no recorded fatalities. In Scotland in 1918, there were 61 cases of solanine poisoning after consumption of potatoes containing 0.41 mg of solanine per gram of potato, resulting in the death of a five-year old. A case report from 1925 reported that 7 family members who ate green potatoes fell ill from solanine poisoning two days later, resulting in the deaths of the 45-year-old mother and 16-year-old daughter. The other family members recovered fully. In another case report from 1959, four members of a British family exhibited symptoms of solanine poisoning after eating jacket potatoes (baked potatoes) containing 0.5 mg of solanine per gram of potato.
=== Polymer chemistry === Although MS-based analyses of polymers have largely been performed using single-stage MS, tandem MS has also been used to characterize polymer components. CID is the most common method of dissociation used, but ETD has been used as a complementary method. Unique bond cleavages resulting from ETD supply valuable diagnostic information.
Sources: en.wikipedia.org
=== Establishment === The British South Africa Police's Special Branch began pseudo operations to collect intelligence in 1966. The Rhodesian Army took part in a joint trial using these tactics with the British South Africa Police and Special Branch that year, but it was not successful for at that stage the black population was largely indifferent to the insurgents and so not able to provide intelligence on them. The ZANLA began to gain control over north-eastern Rhodesia from 1971, and considerably strengthened its influence over the population in the region over the next year. This led to the networks of informers who had provided information to the Rhodesian Government ceasing to do so, which made it difficult for the security forces to locate and counter the insurgents. In response, Special Branch began to establish pseudo teams in January 1973. The Rhodesian Army also formed two such teams in February; these comprised members of C Squadron 22 (Rhodesian) SAS, black soldiers from the Rhodesian African Rifles and former insurgents. These teams enjoyed success, leading to a decision to expand pseudo operations. Major Ronald Francis Reid-Daly was selected to command the unit that became the Selous Scouts in November 1973. He was personally selected for this role by Lieutenant General Peter Walls, the head of the Rhodesian Army. An initial group of 25 personnel were selected and trained at Makuti near Lake Kariba. The first troop completed training and began operations in January 1974, followed by two other troops in February and March that year.
== External links == The chemical logic behind the pentose phosphate pathway Pentose+Phosphate+Pathway at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Pentose phosphate pathway Map – Homo sapiens
It is a legal requirement that an assessment of major organ toxicity be performed (effects on the heart and lungs, brain, kidney, liver and digestive system), as well as effects on other parts of the body that might be affected by the drug (e.g., the skin if the new drug is to be delivered on or through the skin). Such preliminary tests are made using in vitro methods (e.g., with isolated cells), but many tests can only use experimental animals to demonstrate the complex interplay of metabolism and drug exposure on toxicity. However, aside from regulatory requirements, there is a broad range of other factors, such as patient requirements, that are considered during development and testing. The information gathered from this preclinical testing, as well as information on CMC, and submitted to regulatory authorities (in the US, to the FDA), as an Investigational New Drug (IND) application. If the IND is approved, development moves to the clinical phase.
Sources: en.wikipedia.org
Sinosauropteryx was the first non-avian dinosaur to have its life colouration described by scientists based on physical evidence. Some fossils of Sinosauropteryx show an alternation of lighter and darker bands preserved on the tail. Chen and colleagues initially interpreted this banding pattern as an artifact of the splitting between the main slab and counter slab in which the original specimen was preserved. However, Longrich suggested in his 2002 presentation for the Society of Vertebrate Paleontology that these specimens actually preserve remnants of the colouration pattern the animal would have exhibited in life. He argued that the dark, banded areas on the tail were too evenly spaced to have been caused by random separation of the fossil slabs, and that they represent fossilized pigments present in the feathers. Additionally, rather than an artifact of preservation or decomposition, the presence of dark feathers along only the top of the body may also reflect the colour pattern in life, indicating that Sinosauropteryx prima was countershaded with dark colouration on its back and lighter colouration on its underside, with bands or stripes on the tail for camouflage. Longrich's conclusions were supported in a paper first published online in the journal Nature in January 2010. Fucheng Zhang and colleagues examined the fossilized feathers of several dinosaurs and early birds, and found evidence that they preserved melanosomes, the cell components that give the feathers of modern birds their colour.
On the other hand, the reticular fiber of the capillary sheath resembled the basement membrane of the capillary in its components. Because of their affinity for silver salts, these fibers are called argyrophilic.
Krypton is considered to be a non-toxic asphyxiant. Being lipophilic, krypton has a significant anaesthetic effect (although the mechanism of this phenomenon is still not fully clear, there is good evidence that the two properties are mechanistically related), with narcotic potency seven times greater than air, and breathing an atmosphere of 50% krypton and 50% natural air (as might happen in the locality of a leak) causes narcosis in humans similar to breathing air at four times atmospheric pressure. This is comparable to scuba diving at a depth of 30 m (100 ft) and could affect anyone breathing it.
The rattlesnake became a symbolic animal for the Colonials during the Revolutionary War period, and is depicted prominently on the Gadsden Flag. It continues to be used as a symbol by the United States military, and political movements within the United States.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.